The discovery of mutations in specific genes, such as isocitrate dehydrogenase(IDH) gene mutations,3 BRAF mutations,4, 5 and histone mutations,6 has changed our understanding of the pathogenesis of many types of gliomas and subsequently driven the biomarker‐related classification of gliomas.7 Notably, the current role of this classification system is not just as a supplement to diagnosis; instead, it goes beyond histological diagnosis. Here, IDH3A is linked to glioma.